¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"density dependent inhibition"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • temperature-dependent skin disorder
    ¿ÂµµÀÇÁ¸ÇǺκ´
  • vitamin D-dependent rickets
    ºñŸ¹ÎDÀÇÁ¸±¸·çº´
  • antidromic inhibition
    ¿ª¹æÇâ¾ïÁ¦
  • afferent inhibition
    µé½Å°æ¾ïÁ¦, ±¸½É¾ïÁ¦
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • allogenic inhibition
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • competitive inhibition
    °æÀï¾ïÁ¦
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦°Ë»ç
  • contact inhibition
    Á¢Ã˾ïÁ¦
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • feedback inhibition
    µÇ¸ÔÀÓ¾ïÁ¦
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦°Ë»ç
  • hemagglutination-inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ
  • irreversible inhibition
    ºñ°¡¿ª¾ïÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low density lipoprotein
    Àú¹ÐµµÁöÁú´Ü¹é
  • very low density lipoprotein
    ÃÊÀú¹ÐµµÁöÁú´Ü¹é
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • non-insulin-dependent diabetes
    ºñÀν¶¸°ÀÇÁ¸´ç´¢º´
  • noninsulin dependent
    ºñÀν¶¸°ÀÇÁ¸-
  • temperature-dependent skin disorder
    ¿ÂµµÀÇÁ¸ÇǺκ´
  • frequency-dependent
    Á֯ļöÀÇÁ¸Çü
  • hormone dependent tumor
    È£¸£¸óÀÇÁ¸Á¾¾ç
  • insulin-dependent
    Àν¶¸°ÀÇÁ¸-
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸»ó´ëÀ§Çè¸ðµ¨
  • vitamin D-dependent rickets
    ºñŸ¹ÎµðÀÇÁ¸±¸·íº´
  • afferent inhibition
    µé½Å°æ¾ïÁ¦, ±¸½É¾ïÁ¦
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • allogenic inhibition
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • antidromic inhibition
    (¢¡recurrent inhibition) ȸ±Í¾ïÁ¦
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü
  • colony inhibition test
    ¼¼Æ÷±ºÇü¼º¾ïÁ¦°Ë»ç, Áý¶ôÇü¼º¾ïÁ¦°Ë»ç
  • competitive inhibition
    °æÀï¾ïÁ¦, °æÇÕ¾ïÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hypnotic-dependent disorder
    ¼ö¸éÁ¦ÀÇÁ¸Àå¾Ö, ~º´
  • personality disorder, dependent
    ÀÇÁ¸¼º(ëîðíàõ) ÀΰÝÀå¾Ö
  • rate dependent bundle branch block
    ½É¹Ú¼öÀÇÁ¸¼º °¢Â÷´Ü.
  • HDL (High-density lipoproteins)
    °í¹ÐµµÁö´Ü¹éÁú(ÍÔÚËÓøò·Ó±ÛÜòõ)
  • High-density lipoprotein = HDL
    °í¹ÐµµÁö´Ü¹éÁú(ÍÔÚËÓøò·Ó±ÛÜòõ)
  • IDL = intermediate density lipoprotein
    Á߹еµÁö´Ü¹é(ñéÚËÓøò·Ó±ÛÜ)
  • Intermediate density lipoprotein =IDL
    Á߹еµÁö´Ü¹é(ñéÚËÓøò·Ó±ÛÜ)
  • LDL = low density lipoprotein
    Àú¹ÐµµÁö´Ü¹é(î¸ÚËÓøò·Ó±ÛÜ)
  • REM density
    ·½¹Ðµµ
  • VLDL => very low density lipoprotein
    ÃÊÀú¹ÐµµÁö ´Ü¹éÁú
  • amorphous density
    ¹«Á¤Çü ¹Ðµµ(ÙíïÒúþ ÚËÓø)
  • apparent density
    °Ñº¸±â ¹Ðµµ.
  • grain density
    ÀÔÀÚ<±×·¡ÀÎ>¹Ðµµ.
  • high electron density
    °íÀüÀڹеµ(ÍÔï³í­ÚËöô).
  • high-density lipoprotein
    °í¹ÐµµÁö¹æ´Ü¹é
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • diabetes mellitus,non-insulin-dependent
    ºñ-Àν¶¸° ÀÇÁ¸¼º(Þª¡­)
  • edema,dependent
    üÀ§¼º(ô÷êÈàõ)
  • frequency dependent
    Á֯ļö ÀÇÁ¸Çü
  • frequency-dependent
    Á֯ļö ÀÇÁ¸Çü (ñ²÷î⦠ëîðíû¡)
  • hormone dependent
    È£¸£¸óÀÇÁ¸¼º.
  • hormone dependent tumor
    È£¸£¸óÀÇÁ¸¼º Á¾¾ç.
  • hypersensitivity reactions,type ii(antibody-dependent cell-mediate cyt
    IIÇü
  • hypnotic-dependent disorder
    ¼ö¸éÁ¦ÀÇÁ¸Àå¾Ö, ~º´
  • insulin dependent diabetes mellitus =IDDM
    Àν¶¸°ÀÇÁ¸¼º ´ç´¢º´.
  • insulin-dependent DM
    Àν¶¸°ÀÇÁ¸¼º<Á¦ 1 Çü>´ç´¢º´
  • passive dependent
    Çǵ¿ÀÇÁ¸¼º.(Á¤½Å)¼öµ¿ÀÇÁ¸¼º(áôÔÑëîðíàõ)(ÀÇ).
  • personality disorder, dependent
    ÀÇÁ¸¼º(ëîðíàõ) ÀΰÝÀå¾Ö
  • rate dependent bundle branch block
    ½É¹Ú¼öÀÇÁ¸¼º °¢Â÷´Ü.
  • temperature-dependent skin disorders
    ¿ÂµµÀÇÁ¸ ÇǺκ´
  • thymus dependent antigen
    Èä¼±ÀÇÁ¸Ç׿ø, °¡½¿»ùÀÇÁ¸Ç׿ø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • density gradient
    ¹Ðµµ±¸¹è(ÚËÓøÎþÛÕ)
  • density gradient centrifugation
    ¹Ðµµ±¸¹è ¿ø½ÉºÐ¸®(ÚËÓøÎþÛÕêÀãýÝÂ×î)
  • density gradient sedimentation equilibrium
    ¹Ðµµ±¸¹è ħ°­ ÆòÇü(ÚËÓøÎþÛÕöØË½øÁû¬)
  • density gradient sedimentation velocity
    ¹Ðµµ±¸¹è ħ°­ ¼Óµµ(ÚËÓøÎþÛÕöØË½áÜÓø)
  • density gradient zonal centrifugation
    "¹Ðµµ±¸¹è ¿ª¿ø½ÉºÐ¸®(ÚËÓøÎþÛÕæ´êÀãýÝÂ×î), (ÔÒ) density gradient sedimentation velocity"
  • discontinuous density gradient
    ºÒ¿¬¼Ó ¹Ðµµ±¸¹è(ÝÕææáÙÚËÓøÎþÛÕ)
  • exponential density gradient
    Áö¼ö ³óµµ ±¸¹è (ò¦â¦ÒØÓøÎøÛÎ)
  • familial high-density lipoprotein deficiency °¡Á·¼º °í¹Ðµµ ÁöÁú´Ü¹éÁú °áÇÌ (Ê«ðéàõÍÔÚËÓøò·òõ
    Ó±ÛÜòõÌÀù¹)
  • high-density lipoprotein
    °í¹Ðµµ ÁöÁú´Ü¹éÁú(ÍÔÚËÓøò·òõÓ±ÛÜòõ)
  • linear density gradient
    ¼± ¹Ðµµ(à»ÚËÓø)±â¿ï±â
  • low-density fraction
    Àú¹ÐµµºÐȹ(î¸ÚËÓøÝÂüñ)
  • low-density lipoprotein
    Àú¹Ðµµ Áö´Ü¹éÁú(î¸ÚËÓøò·Ó±ÛÜòõ)
  • optical density
    Èí±¤µµ(ýåÎÃÓø)
  • sucrose density gradient
    ½´Å©·Î½º ¹Ðµµ ±¸¹è(ÚËÓøÎøÛÎ)
  • superhelix density
    Ãʳª¼± ¹Ðµµ (õ±Õ¢àÁÚËÓø)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • interstitial density
    °£Áú¼ºÀ½¿µ
  • linear density
    ¼±»óÀ½¿µ
  • magnetic flux density
    ÀÚ±âÀ¯µ¿¹Ðµµ
  • middle density
    Áß°£À½¿µ, Áß°£¹Ðµµ
  • nodular density
    °áÀý¼ºÀ½¿µ
  • perihilar density
    Æó¹®ÁÖÀ§À½¿µ
  • pixel density
    Çȼ¿À½¿µ, È­¼ÒÀ½¿µ
  • proton (spin) density
    ¾çÀڹеµ
  • proton density contrast
    ¾çÀڹеµ´ëÁ¶
  • proton density weighted image
    ¾çÀڹеµ°­Á¶¿µ»ó
  • proton density weighting
    ¾çÀÚ°­Á¶
  • reticular density
    ¸Á»óÀ½¿µ
  • shadow density
    À½¿µ¹Ðµµ
  • spin density
    ½ºÇɹеµ
  • spin density weighted image
    ½ºÇɹеµ°­Á¶¿µ»ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HD Haab-Dimmer [syndrome]; Hajna-Damon [broth]; Hansen disease; hearing distance; heart disease; helix ...
PSD particle size distribution; peptone, starch, and dextrose; periodic synchronous discharge; phase-sen...
LAI assay Leukocyte Adherence Inhibition assay
MIF   1) Mllerian Inhibiting Factor
  2) Migrating Inhibition Factor
TBII TSH Binding Inhibiting(= Inhibition) Immunoglobulin
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HAI Haemagglutination Inhibition
HI Haemagglutination Inhibition
HI Haemagglutination inhibition test
HIT Hemagglutination inhibition test
HLI Hemolysis inhibition
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • enzyme inhibition
    È¿¼Ò ¾ïÁ¦
  • factor macrophage migration inhibition
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ
  • hapten inhibition test
    ÇÕÅÙ ÀúÇØ ½ÃÇè
    Ç×üÀÇ Ç׿ø Ư¼ö °áÇÕ ºÎÀ§¸¦ µ¤´Â ÇÕÅÙÀ» ÀÌ¿ëÇÏ¿© Ç׿ø °áÁ¤±âÀÇ Ç÷ûÇÐÀû Ư¼ºÀ» °Ë»çÇÏ´Â ½ÃÇè.
  • hemagglutination inhibition test
    ÀûÇ÷±¸ ÀÀÁý ¾ïÁ¦ ½ÃÇè
  • inhibition
    ¾ïÁ¦, ÀúÁö, ÀúÇØ
    °úÁ¤ÀÇ ¾ï¾Ð
  • inhibition reaction
    ¾ïÁ¦, ¾ïÁ¦ ¹ÝÀÀ, ÀúÁö, ÀúÁö ¹ÝÀÀ
  • inhibition zone
    ¾ïÁ¦´ë
    ħ°­ ¶Ç´Â ÀÀÁý ¹ÝÀÀ¿¡¼­ Ç×ü ³óµµ°¡ ³ôÀº Ç÷û¿¡¼­´Â Ç׿ø ÀÔÀÚ¿Í ¹ÝÀÀÀ» ³ªÅ¸³»Áö ¾Ê´Â Çö»ó.
  • lateral inhibition
    Ãø¹æ ¾ïÁ¦
    ÈïºÐÇϰí ÀÖ´Â ¿ä¼Ò¿¡ ÀÇÇÏ¿© ÀÎÁ¢ÇÏ´Â ¿ä¼ÒÀÇ È°µ¿ÀÌ ¾ïÁ¦µÇ´Â Çö»ó.
  • lingering inhibition

    lingissimus capitis (µÎÃÖÀå±Ù

    »óÃø 4¡­5 ÈäÃßÀÇ È¾µ¹±â¿Í ÇÏÃø 3¡­4 °æÃßÀÇ °üÀýµ¹±â¿¡¼­ ±â½ÃÇÏ¿© ÃøµÎ°ñÀÇ À¯¾çµ¹±â¿¡¼­ Á¤ÁöÇÑ´Ù. °æ ½Å°æ °¡ÁöÀÇ Áö¹è¸¦ ¹ÞÀ¸¸ç, ¸Ó¸®¸¦ ÈĹæÀ¸·Î ´ç±â°í ȸÀü½ÃŲ´Ù.
  • myelinated afferent inhibition
    À¯¼öÃÊ ±¸½É¼º ¾ïÁ¦
  • negative feedback inhibition
    À½¼º µÇ¸ÔÀ̱⠾ïÁ¦
  • noncompetitive inhibition
    ºñ°æÇÕÀû ÀúÇØ
  • postsynaptic inhibition
    ½Ã³³½º ÈÄ ¾ïÁ¦
  • segmented inhibition
    ºÐÀýµÈ ¹æÇØ
  • self inhibition
    Àڱ⠾ïÁ¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
density 1. <radiology> The amount of darkness or light in an area of a scan reflects the compactness and density of tissue. Differences in tissue density are the basis for CT and MR scans.
2. <microscopy> Logarithm to the base 10 of the reciprocal of transmittance.
(12 Jan 1998)
density gradient <chemistry> A column of liquid in which the density varies continually with position, usually as a consequence of variation of concentration of a solute.
Such gradients may be established by progressive mixing of solutions of different density as for example: sucrose gradients) or by centrifuge induced redistribution of solute (as for caesium chloride gradients).
Density gradients are widely used for centrifugal and gravity induced separations of cells, organelles and macromolecules. The separations may exploit density differences between particles or primarily differences in size, in which latter case the function of the gradient is chiefly to stabilise the liquid column against mixing.
(12 Jan 1998)
density gradient centrifugation <technique> High-speed centrifugation inwhich molecules float at a point wheretheir density equals that in a gradient of cesium chloride or sucrose.
(12 Jan 1998)
incidence density The person-time incidence rate.
(05 Mar 2000)
intermediate density lipoprotein Class of lipoproteins formed in degradation of very-low-density lipoproteins; about half are cleared quickly from the plasma into the liver by receptor-mediated endocytosis; the other half are degraded into low density lipoproteins.
(05 Mar 2000)
inverse density dependence <epidemiology> See density dependence.
(05 Dec 1998)
optical density 1. <chemistry, investigation> Absorbance is defined as a logarithmic function of the percent transmission of a wavelength of light through a liquid.
2. <microbiology> This can be used as a measure of the amount of light absorbed by a suspension of bacterial cells or a solution of an organic molecule, it is measured by a colourimeter or spectrophotometer.
Absorbance values are used to plot the growth of bacteria in suspension cultures and to gauge the purity and concentration of molecules (such as proteins) in solution.
See: absorption.
(15 Jan 1998)
organismal density <microbiology> Number of organisms or items per unit area or volume.
(09 Oct 1997)
either particle flux density The particle fluence rate, or energy flux density, the energy fluence rate of intensity.
Compare: fluence.
(05 Mar 2000)
familial high density lipoprotein deficiency Familial high {density lipoprotein deficiency}; a heritable disorder of lipid metabolism characterised by almost complete absence from plasma of high density lipoproteins, and by storage of cholesterol esters in foam cells, tonsillar enlargement, an orange or yellow-gray colour of the pharyngeal and rectal mucosa, hepatosplenomegaly, lymph node enlargement, corneal opacity, and peripheral neuropathy; autosomal recessive inheritance.
Synonym: familial high {density lipoprotein deficiency}, Tangier disease.
Origin: G. An-, priv., + alpha, a, + lipoprotein + -aemia, blood
(05 Mar 2000)
flux density <radiobiology> Total amount of a quantity passing through a unit surface area in unit time
See: flux.
(09 Oct 1997)
low density lipoprotein <biochemistry> A lipoprotein substances (combination of a fat and a protein) which acts as a carrier for cholesterol and fats in the bloodstream.
High levels of low density lipoprotein are considered a positive risk factor for the development of coronary artery disease. Less than 130 mg/dl is desirable, 130 to 159 mg/dl is borderline high, over 160 is considered high.
Acronym: LDL
(10 Jan 1998)
low density lipoprotein receptor <biochemistry> A cell surface protein that mediates the endocytosis of low density lipoprotein by cells.
Genetic defects in low density lipoprotein receptors lead to abnormal serum levels of low density lipoprotein and hypercholesterolaemia.
(16 Mar 1998)
low-density lipoprotein receptors Receptors on the surface of cells, especially liver cells, which bind to low density lipoprotein and promote clearance of LDL from the plasma.
(05 Mar 2000)
allogeneic inhibition Inhibition or injury to allogeneic cells that occurs when lymphocytes are mixed and cultured with other cells of different genotypes in vitro.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • probability density function
    È®·ü ¹Ðµµ ÇÔ¼ö )
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á